In vivo regulation of the Alzheimers disease beta-secretase, BACE1

Funded Activity Summary

Dementia claims 1000 Australians weekly. Alzheimer's disease (AD) is the leading cause of dementia. A hallmark of AD is the presence of beta-amyloid (Ab) plaques in brain. Accumulation of Ab leads to toxicity and cell death. We will use cutting-edge technologies to reduce the level of an enzyme (BACE1) that generates Ab. This study will provide seminal information relating to in vivo regulation of Ab and establish a foundation for our ultimate goal of decreasing BACE1 and Ab in human brain.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $287,659.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical infection agents (incl. prions)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Ageing and dementia | Alzheimer's disease | Central nervous system | Gene regulation | Molecular basis of disease | Molecular neuroscience | Neurodegenerative and age-related diseases | RNA interference

Related Links